1 – 10 of 38
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2014
- EMAS position statement: menopause for medical students
- The vaginal microbiota: what have we learned after a decade of molecular characterization?
- Venous thrombo-embolism as a complication of cross-sex hormone treatment of male-to-female transsexual subjects: a review
- Herbal preparations for the menopause: beyond isoflavones and black cohosh
- 2013
- Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
- EMAS position statement: diet and health in midlife and beyond
- Quality of life in sarcopenia and frailty
- An evaluation of the Fracture Risk Assessment Tool (FRAX®) as an indicator of treatment efficacy: the effects of bazedoxifene and raloxifene on vertebral, nonvertebral, and all clinical fractures as a function of baseline fracture risk assessed by FRAX®
- Treatment of osteoporosis in men
- Effect on bone turnover markers of once-yearly intravenous infusion of zoledronic acid versus daily oral risedronate in patients treated with glucocorticoids